



GENSIGHT BIOLOGICS
A French Société Anonyme (corporation)
with share capital of 1,158,389.78 Euros
74 rue du Faubourg Saint Antoine
75012 Paris
751 164 757 - Paris Trade and Companies Registry

**NOMINATION OF MRS DE CRAECKER AS DIRECTOR, GENERAL MEETING OF
JUNE 21, 2023**

USUAL NAME: Françoise DE CRAECKER

PERSONAL HOME ADDRESS: 26 Avenue du Yorkshire 1200 Woluwe Saint Lambert,
BELGIUM

DATE AND PLACE OF BIRTH: 22/12/1961 in Ixelles, BELGIUM

OFFICES THAT EXPIRED IN THE LAST FIVE YEARS IN OTHER COMPANIES:

Françoise de Craecker, M.D., has served as independent director since 2021.

Françoise de Craecker led the EMEA (Europe, Middle East & Africa) region at AveXis, further acquired by Novartis. She built from scratch the multifunctional team launching Zolgensma, the first one-shot Gene Therapy for the treatment of Spinal Muscular Atrophy, in the EMEA region. She paved the way for the approval, distribution, market access and commercialization, working with authorities on innovative funding pathways and early access. She also established a wide presence in the main European markets and a network of distributors in the Middle East and other European countries. Prior to joining AveXis, Mrs. de Craecker was leading EMEA operations for Raptor Pharmaceuticals (later acquired by Horizon and Chiesi) at the critical phase of a shift from R&D to commercialization of their lead product in Cystinosis, followed by the launch of their acquired product in Cystic Fibrosis. Before that, she was at Shire Human Genetics for 14 years. Originally, she was part of the team launching the first Orphan Drug approved in Europe. She then took different positions of increasing responsibilities and led various strategic and operational teams, locally and globally based in different European countries and USA.

Mrs. de Craecker holds a Master's in Science from the Faculty of Medicine of the University of Leuven (Belgium).

OFFICES IN THE COMPANY: Independent director, member of the Nominations Committee and Chairman of the Compensation Committee

NUMBER OF SHARES OF THE CORPORATION OWNED: 0



GENSIGHT BIOLOGICS
A French Société Anonyme (corporation)
with share capital of 1,158,389.78 Euros
74 rue du Faubourg Saint Antoine
75012 Paris
751 164 757 - Paris Trade and Companies Registry

**NOMINATION OF MR GOODFELLOW AS DIRECTOR, GENERAL MEETING OF
JUNE 21, 2023**

USUAL NAME: Peter GOODFELLOW

PERSONAL HOME ADDRESS: 14 Parliament Hill, London, NW3 2SY, UK

DATE AND PLACE OF BIRTH: 04/08/1951 in London, UK

OFFICES THAT EXPIRED IN THE LAST FIVE YEARS IN OTHER COMPANIES:

Peter Goodfellow, Ph.D. has served as a director since June 2014.

Peter Goodfellow is a scientific consultant for Abingworth and the Bill and Melinda Gates Foundation.

Dr. Goodfellow was previously the Balfour Professor of Genetics at Cambridge University before working for SmithKline Beecham (later GlaxoSmithKline) as head of research.

He has founded several biotechnology companies and has sat on the boards of Gamma Delta Therapeutics, Adaptate Biotherapeutics and several medical charities.

Dr. Goodfellow holds doctorates from Oxford and Bristol Universities.

OFFICES IN THE COMPANY: Independent director

NUMBER OF SHARES OF THE CORPORATION OWNED: 0